Abstract 5139
Background
The prognostic value of the inflammatory indexes (eg. neutrophil-to-lymphocyte ratio, NLR; and systemic immune-inflammation index, SII) was demonstrated among patients with epithelial ovarian cancer (EOC). This study aimed to evaluate their predictive value in terms of platinum-free interval (PFI) as regard to bevacizumab treatment received.
Methods
A total of 375 EOC patients were retrospectively analyzed, 301 treated with chemotherapy alone and 74 with bevacizumab, with the decision to include this drug in the chemotherapy regimen left to the discretion of the treating physician. The correlation between NLR (defined as the ratio of neutrophil to lymphocyte count) and SII, calculated as (platelet count × neutrophil count)/lymphocyte count, and PFI were analyzed using logistic regression analyses adjusted for baseline patient characteristics. Cutoff values were determined using Receiver Operating Characteristic (ROC) analysis.
Results
In univariate analysis, patients with high NLR (≥3) and SII (≥730) had a significantly shorter PFI at 6 and 12 months in overall cohort. In multivariate analysis, only NLR was an independent predictive factor for PFI at 6 months (OR = 2.52, 95% CI 1.30–4.87, p = 0.006) and at 12 months (OR = 2.05, 95% CI 1.05–4.01, p = 0.036) in the overall population and in the chemotherapy group (OR = 2.77, 95% CI 1.38–5.56, p = 0.004; HR = 2.27, 95% CI 1.10–4.70, p = 0.027, respectively). Inflammatory indexes were not predictive for PFI in the bevacizumab group (Table).Table: 1020P
| PFI at 6 months | PFI at 12 months | |||||||
|---|---|---|---|---|---|---|---|---|
| N. pts | N. pts | OR (95% CI) | p | N. pts | N. pts | OR (95% CI) | p | |
| NLR | ||||||||
| <3 | 74 | 139 | 1.00 | 113 | 98 | 1.00 | ||
| ≥3 | 80 | 68 | 2.52 (1.30-4.87) | 0.006 | 106 | 37 | 2.05 (1.05-4.01) | 0.036 |
| SII | ||||||||
| <730 | 52 | 99 | 1.00 | 76 | 73 | 1.00 | ||
| ≥730 | 102 | 108 | 0.74 (0.36-1.53) | 0.413 | 143 | 62 | 0.91 (0.45-1.84) | 0.786 |
| CT | ||||||||
| NLR | ||||||||
| <3 | 62 | 115 | 1.00 | 98 | 78 | 1.00 | ||
| ≥3 | 69 | 48 | 2.77 (1.38-5.56) | 0.004 | 89 | 24 | 2.27 (1.10-4.70) | 0.027 |
| SII | ||||||||
| <730 | 41 | 80 | 1.00 | 63 | 56 | 1.00 | ||
| ≥730 | 90 | 83 | 0.76 (0.35-1.67) | 0.498 | 124 | 46 | 0.84 (0.39-1.82) | 0.663 |
| CT+B | ||||||||
| NLR | ||||||||
| <3 | 12 | 24 | 1.00 | 15 | 20 | 1.00 | ||
| ≥3 | 11 | 20 | 0.47 (0.04-5.15) | 0.538 | 17 | 13 | 0.75 (0.11-5.25) | 0.774 |
| SII | ||||||||
| <730 | 11 | 19 | 1.00 | 13 | 17 | 1.00 | ||
| ≥730 | 12 | 25 | 1.65 (0.13-20.56) | 0.696 | 19 | 16 | 1.78 (0.21-15.14) | 0.599 |
Conclusions
The NLR was an independent predictive factor for platinum-sensitivity in patients with EOC treated with chemotherapy. Its predictive role seems to be lost in patients treated with bevacizumab.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MITO group.
Funding
MITO group.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2551 - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.
Presenter: Benedetta Conte
Session: Poster Display session 2
Resources:
Abstract
3426 - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).
Presenter: Sonja Vliek
Session: Poster Display session 2
Resources:
Abstract
3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Presenter: Gustavo Werutsky
Session: Poster Display session 2
Resources:
Abstract
4044 - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.
Presenter: Mark De Ridder
Session: Poster Display session 2
Resources:
Abstract
719 - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Presenter: Justin Stebbing
Session: Poster Display session 2
Resources:
Abstract
3595 - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival
Presenter: Axel Berthelot
Session: Poster Display session 2
Resources:
Abstract
3992 - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.
Presenter: Maria Vittoria Dieci
Session: Poster Display session 2
Resources:
Abstract
3477 - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Presenter: Mellissa Williamson
Session: Poster Display session 2
Resources:
Abstract
3928 - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Presenter: Hans Tesch
Session: Poster Display session 2
Resources:
Abstract
2184 - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract